INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold ...

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breas...

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™...

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe...

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update...

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given ...

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point...

INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use o...

INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wed...

INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Glob...

INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcar...

INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update...

INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference...

INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on M...

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference....

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patie...

INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and D...

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at Interna...

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy...

INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update...

INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on We...

XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease...

INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcom...

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ t...

INmune Bio, Inc. Announces 2022 Results and Provides Business Update...

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update ...

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Austra...

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne...